- Home
- For Healthcare Professionals
For Healthcare Professionals
Physicians Report Winter 2012
The Colorado Blood Cancer Institute Winter Newsletter has important information from three of our team specialists.
Jeffrey Matous, MD _ Novel Therapy for Hodgkin Lymphoma Patients
The year 2011 witnessed the FDA approval of a novel therapy for patients for whom we have desperately needed new options: those Hodgkin Lymphoma (HL) patients not cured by frontline therapy nor by second line autologous stem cell transplantation (ASCT), and patients with anaplastic large cell non-Hodgkin
lymphoma (ALCL) who fail initial therapy.
Read more...
Richard Nash, MD _ Systemic Sclerosis: Hematopoietic Cell Transplataion
Hematopoietic (blood) cell transplantation (HCT) is a procedure that is now routinely used for treatment of hematological malignancies. The source of the blood stem cell can be from one’s own blood (autologous) or from a donor (allogeneic). Both types of transplantation can have a profound effect on the immune system. After intensive chemotherapy followed by autologous HCT, depletion of autoreactive immunologic memory has been observed. After allogeneic HCT, the autoreactive immune system is replaced by a donorderived immune system without the predisposition to damage organs which were targets of the autoimmune disease.
Read more...
Peter McSweeney, MD _ Nonmyeloablative AllogeneicTransplants for Older Patients with Hematological Malignancies
Over the last 15 years so-called reduced intensity allogeneic transplants emergedfrom being an experimental form of transplantation into a broadly applied therapeutic modality. The treatment was developed to allow allogeneic transplants to be performed in older or otherwise medically less fit patients who wouldn’t qualify for this type of treatment. Critical aspects of this therapy is the use of lowintensity better-tolerated transplant regimens and reliance on graft-versus-tumor effects to achieve the therapeutic goal of suppressing the patient’s cancer. This therapy has been almost exclusively used in treating hematological malignancies where the host hematopoietic system is a good target for donor immune cell attack. While large randomized studies of this modality are still lacking, phase 2 studies have demonstrated that potent antitumor effects accompany these transplants, predominantly demonstrated through induction and sustaining of remissions of high risk hematological malignancies.
Read More...
2011 Ash Review
Sarah Cannon in collaboration with the Colorado Blood Cancer Institute present the 2011 Ash Review -"Updates in the Treatment and Management of Hematologic Malignancies".
Thursday, February 9, 2012, 5-9 PM
To Pre-register:
Website: www.thecbce.com/denver
Email: info@thecbce.com
Phone: 214-260-9024
For more information contact:
Vicki Snider 720-754-4897